Antiplatelet agents for the treatment and prevention of coronary atherothrombosis
Antiplatelet drugs provide first-line antithrombotic therapy for the management of acute ischemic syndromes (both coronary and cerebrovascular) and for the prevention of their recurrence. Their role in the primary prevention of atherothrombosis remains controversial because of the uncertain balance...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Elsevier
2017
|
| _version_ | 1797083822674673664 |
|---|---|
| author | Patrono, C Morais, J Baigent, C Collet, J Fitzgerald, D Halvorsen, S Rocca, B Siegbahn, A Storey, R Vilahur, G |
| author_facet | Patrono, C Morais, J Baigent, C Collet, J Fitzgerald, D Halvorsen, S Rocca, B Siegbahn, A Storey, R Vilahur, G |
| author_sort | Patrono, C |
| collection | OXFORD |
| description | Antiplatelet drugs provide first-line antithrombotic therapy for the management of acute ischemic syndromes (both coronary and cerebrovascular) and for the prevention of their recurrence. Their role in the primary prevention of atherothrombosis remains controversial because of the uncertain balance of the potential benefits and risks when combined with other preventive strategies. The aim of this consensus document is to review the evidence for the efficacy and safety of antiplatelet drugs, and to provide practicing cardiologists with an updated instrument to guide their choice of the most appropriate antiplatelet strategy for the individual patient presenting with different clinical manifestations of coronary atherothrombosis, in light of comorbidities and/or interventional procedures. |
| first_indexed | 2024-03-07T01:46:53Z |
| format | Journal article |
| id | oxford-uuid:98b5d6a1-7186-4554-bead-3e28ffbce9ee |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T01:46:53Z |
| publishDate | 2017 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:98b5d6a1-7186-4554-bead-3e28ffbce9ee2022-03-27T00:09:02ZAntiplatelet agents for the treatment and prevention of coronary atherothrombosisJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:98b5d6a1-7186-4554-bead-3e28ffbce9eeEnglishSymplectic Elements at OxfordElsevier2017Patrono, CMorais, JBaigent, CCollet, JFitzgerald, DHalvorsen, SRocca, BSiegbahn, AStorey, RVilahur, GAntiplatelet drugs provide first-line antithrombotic therapy for the management of acute ischemic syndromes (both coronary and cerebrovascular) and for the prevention of their recurrence. Their role in the primary prevention of atherothrombosis remains controversial because of the uncertain balance of the potential benefits and risks when combined with other preventive strategies. The aim of this consensus document is to review the evidence for the efficacy and safety of antiplatelet drugs, and to provide practicing cardiologists with an updated instrument to guide their choice of the most appropriate antiplatelet strategy for the individual patient presenting with different clinical manifestations of coronary atherothrombosis, in light of comorbidities and/or interventional procedures. |
| spellingShingle | Patrono, C Morais, J Baigent, C Collet, J Fitzgerald, D Halvorsen, S Rocca, B Siegbahn, A Storey, R Vilahur, G Antiplatelet agents for the treatment and prevention of coronary atherothrombosis |
| title | Antiplatelet agents for the treatment and prevention of coronary atherothrombosis |
| title_full | Antiplatelet agents for the treatment and prevention of coronary atherothrombosis |
| title_fullStr | Antiplatelet agents for the treatment and prevention of coronary atherothrombosis |
| title_full_unstemmed | Antiplatelet agents for the treatment and prevention of coronary atherothrombosis |
| title_short | Antiplatelet agents for the treatment and prevention of coronary atherothrombosis |
| title_sort | antiplatelet agents for the treatment and prevention of coronary atherothrombosis |
| work_keys_str_mv | AT patronoc antiplateletagentsforthetreatmentandpreventionofcoronaryatherothrombosis AT moraisj antiplateletagentsforthetreatmentandpreventionofcoronaryatherothrombosis AT baigentc antiplateletagentsforthetreatmentandpreventionofcoronaryatherothrombosis AT colletj antiplateletagentsforthetreatmentandpreventionofcoronaryatherothrombosis AT fitzgeraldd antiplateletagentsforthetreatmentandpreventionofcoronaryatherothrombosis AT halvorsens antiplateletagentsforthetreatmentandpreventionofcoronaryatherothrombosis AT roccab antiplateletagentsforthetreatmentandpreventionofcoronaryatherothrombosis AT siegbahna antiplateletagentsforthetreatmentandpreventionofcoronaryatherothrombosis AT storeyr antiplateletagentsforthetreatmentandpreventionofcoronaryatherothrombosis AT vilahurg antiplateletagentsforthetreatmentandpreventionofcoronaryatherothrombosis |